ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: L15 • ACR Convergence 2024

    LEVI-04, a Novel neurotrophin-3 Inhibitor, Substantially Improves Pain and Function Without Deleterious Effects on Joint Structure in People with Knee Osteoarthritis: A Randomized Controlled Phase II Trial

    Philip Conaghan1, Ali Guermazi2, Nathaniel Katz3, Asger Bihlet4, Dror Rom5, Michael Perkins6, Bernadette Hughes6, Claire Herholdt6, Iwona Bombelka6 and Simon Westbrook6, 1University of Leeds, Leeds, United Kingdom, 2Boston University, West Roxbury, MA, 3Rin Sof Innovation, Ltd, Boston, MA, 4NBCD A/S, Soeborg, Denmark, 5Prosoft Clinical, Chesterbrook, 6Levicept Ltd, Ramsgate, United Kingdom

    Background/Purpose: There is an urgent need for new therapies to treat OA. Excess neurotrophins (NT) are implicated in OA and other painful conditions. Previous OA…
  • Abstract Number: L13 • ACR Convergence 2024

    Anifrolumab Long-Term Treatment Is More Effective Against Organ Damage Than Standard of Care Alone: Results from an External Control Arm Study on Organ Damage in Phase 3 Clinical Trials and the University of Toronto Lupus Clinic Cohort

    Zahi Touma1, Ian Bruce2, Richard A. Furie3, Eric Morand4, Raj Tummala5, Shelly Chandran6, Gabriel Abreu7, Jacob Knagenhjelm7, Kellyn Arnold8, Hopin Lee8, Eleanor Ralphs8, Danuta Kielar9, Aleksander Bedenkov9 and Miina Waratani9, 1Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, 2Queen's University Belfast, Belfast, United Kingdom, 3Northwell Health, Manhasset, NY, 4Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, 5BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 6Astrazeneca, Mississauga, ON, Canada, 7BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 8IQVIA, London, United Kingdom, 9Biopharmaceuticals Medicine, AstraZeneca, Cambridge, United Kingdom

    Background/Purpose: In SLE, persistent disease activity, disease flares and long-term glucocorticoid (GC) use all contribute to organ damage accrual. The effects of novel therapies on…
  • Abstract Number: L20 • ACR Convergence 2024

    Automated Ultrasound System ARTHUR with AI Analysis DIANA Matches Expert Rheumatologist in Hand Joint Assessment of Rheumatoid Arthritis Patients

    Bill Aplin Frederiksen1, Mads Ammitzbøll Danielsen2, Hilde Berner Hammer3, Benjamin Schultz Overgaard1, Anders Weber4, Lene Terslev2, Thiusius Rajeeth Savarimuthu5 and Soren Andreas Just1, 1Section of Rheumatology, Department of Medicine, Svendborg Sygehus OUH, Svendborg, Denmark, 2Center for Rheumatology and Spine Disease, Rigshospitalet, Glostrup, Denmark, 3Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Faculty of Medicine, University of Oslo, Oslo, Norway, 4ROPCA, Odense, Denmark, 5Mærsk Mc-Kinney Møller Institute, University of Southern Denmark, Odense, Denmark

    Background/Purpose: To evaluate the precision of ARTHUR (Figure 1), a CE-marked, fully automated ultrasound scanning system that captures ultrasound images of 22 hand joints and…
  • Abstract Number: L09 • ACR Convergence 2024

    Efficacy and Safety of Tofacitinib in Patients with Active Systemic Juvenile Idiopathic Arthritis

    Hermine Brunner1, Caifeng Li2, Kogie Chinniah3, Yosef Uziel4, Olga Synoverska5, Sujata Sawhney6, Inmaculada Calvo Penades7, Ingrid Clara Louw8, Meiping Lu9, Pooja Nikunj Patel10, Pamela F. Weiss11, Cheng Chang12, Ivana Vranic13, Shixue Liu14, Annette Diehl15, Jose L. Rivas16, Carol A. Connell17, Gary G. Koch18, Alberto Martini19, Daniel J. Lovell1, Nicolino Ruperto20 and the PRINTO and PRCSG investigators, 1Cincinnati Children’s Hospital Medical Center, and University of Cincinnati, Cincinnati, OH, 2Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Bejing, China, 3Department of Paediatrics and Child Health, University of Kwa-Zulu, and Enhancing Care Foundation, Durban, South Africa, 4Pedriatric Rheumatology Unit, Department of Pediatrics, Meir Medical Center and Israel Tel Aviv University School of Medicine, Kfar Saba, Israel, 5Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine, 6Sir Ganga Ram Hospital, New Delhi, India, 7Hospital Universitario y Politécnico La Fe, Valencia, Spain, 8Panorama Medical Centre, Cape Town, South Africa, 9Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China, 10Ann & Robert H. Lurie Children’s Hospital of Chicago; Northwestern University School of Medicine, Chicago, IL, 11Division of Rheumatology, Children's Hospital of Philadelphia, and University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 12Pfizer Inc, New York, NY, 13Pfizer Ltd, Tadworth, United Kingdom, 14Pfizer Inc, Shanghai, China, 15Pfizer Inc, Collegeville, PA, 16Pfizer SLU, Madrid, Spain, 17Pfizer Inc, Groton, CT, 18University of North Carolina at Chapel Hill, Chapel Hill, NC, 19University of Genoa, Genoa, Italy, 20Università Milano Bicocca, Milano, and IRCCS Fondazione San Gerardo dei Tintori, Monza, Italy

    Background/Purpose: Tofacitinib (TOF) has been shown to be efficacious in the treatment of polyarticular course JIA, including systemic JIA (sJIA) without active systemic features. Here…
  • Abstract Number: L07 • ACR Convergence 2024

    The Classification Criteria for Anti-Synthetase Syndrome (Class) Project

    Giovanni Zanframundo1, Sara Faghihi Kashani2, Akira Yoshida3, Eduardo Dourado4, Iazsmin Bauer Ventura5, Daphne Rivero Gallegos6, Aravinthan Loganathan7, Gianluca Sambataro8, Francisca Bozan9, Sangmee Bae10, Darosa Lim11, Marta Cheli12, Yasuhiko Yamano13, Francesco Bonella14, Tamera Corte15, Tracy J. Doyle16, David Fiorentino17, Miguel Gonzalez-Gay18, Marie Hudson19, Masataka Kuwana20, Ingrid Lundberg21, Andrew Mammen22, Neil McHugh23, Frederick Miller24, Carlomaurizio Montecucco1, Chester Oddis25, Jorge Rojas-Serrano6, Jens Schmidt26, Carlo Alberto Scirè27, Albert Selva-O'Callaghan28, Victoria Werth11, Davide Rozza29, Monica Morosini30, Sara Bozzini30, Lorenzo Cavagna1, Rohit Aggarwal25 and the CLASS project investigators, 1Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, 2University of Pittsburgh School of Medicine, Pittsburgh, PA, USA and University of California, San Francisco, CA, 3Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan, 4Unidade Local de Saùde da Regiao de Aveiro and Aveiro Rheumatology Research Centre, Aveiro, Portugal; Universidade de Lisboa, Lisboa, Portugal, 5University of Chicago, Chicago, IL, 6Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío Villegas, Mexico City, Mexico, 7Royal National Hospital for Rheumatic Diseases and University of Bath, UK; Arthritis Australia, Broadway, Glebe, NSW, Australia, 8University of Enna "Kore", Enna, Italy, 9Hospital Clinico Universidad de Chile, Santiago de Chile, Chile, 10UCLA, Los Angeles, CA, 11University of Pennsylvania, Philadelphia, PA, 12Fondazione IRCCS Istituto Neurologico C. Besta, Milano, Italy, 13Tosei General Hospital, Aichi, Japan, 14University of Duisburg-Essen, Essen, Germany, 15Royal Prince Alfred Hospital and University of Sydney, Sydney, Australia, 16Brigham and Women's Hospital, Boston, MA, 17Stanford University, Redwood City, CA, 18IIS-Fundación Jiménez Díaz, Madrid, Spain, 19McGill University, Montreal, QC, Canada, 20Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 21Karolinska Institutet, Stockholm, Sweden, 22NIH, Bethesda, MD, 23University of Bath, Bath, United Kingdom, 24NIH, NIEHS, Durham, NC, 25University of Pittsburgh, Pittsburgh, PA, 26University Medical Center Goettingen, Goettingen, Germany, 27Univeristy of Milano Bicocca, Milan, Italy and IRCCS San Gerardo dei Tintori Foundation, Monza, Italy, 28Hospital Universitari Vall d'Hebron, Barcelona, Spain, 29Italian Society for Rheumatology, Milano, Italy, 30Fondazione IRCCS Policlinico San Matteo Hospital of Pavia, Pavia, Italy

    Background/Purpose: The aim of this study was to develop and validate new classification criteria for Anti-Synthetase Syndrome (ASSD) using data and consensus driven methodologies and…
  • Abstract Number: L08 • ACR Convergence 2024

    A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-ranging and Parallel-group Study to Evaluate the Safety and Efficacy of XG005 in Subjects with Painful Osteoarthritis of the Knee

    Limin Ren1, Wenjie Zheng2, Zhenpeng Guan3, Yang Zhang4, Zeyu Huang5, Tong Li6, Yuwei Peng7, Qiuli Wu8, Wei Gou9, Wei Zhao10, Pengyan Qiao11, Xiaoli Pan12 and Guang-Liang Jiang13, 1Peking University, People’s Hospital, Rheumatology and Immunology Department, Beijing, China, 2Yantai Yuhuangding Hospital of Qingdao University, Department of Orthopedics, Yantai, China, 3Peking University, Shougang Hospital, Department of Orthopedics, Beijing, China, 4Division of Orthopaedic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, 5West China Hospital of Sichuan University, Department of Orthopedics, Chengdu, China, 6Xiangya Hospital of Central South University, Rheumatology and Immunology Department, Changsha, China, 7PingXiang People’s Hospital, Rheumatology and Immunology Department, Pingxiang, China, 8Tianjin Medical University General Hospital, Department of Orthopedics, Tianjin, China, 9Hebei Petrochina Central Hospital, Rheumatology and Immunology Department, Langfang, China, 10Central Hospital Affiliated to Shenyang Medical College, Department of Orthopedics, Shenyang, China, 11Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Rheumatology and Immunology Department, Taiyuan, China, 12Affiliated Hospital of Zunyi Medical University, Rheumatology and Immunology Department, Zunyi, China, 13Xgene Pharmaceutical, Lexington, MA

    Background/Purpose: Osteoarthritis (OA) affects 595 million people globally; cases are projected to increase 49-95% for various joints by 2050 as populations age (GBD 2023). OA…
  • Abstract Number: L14 • ACR Convergence 2024

    A Withdrawal Study of Colchicine in Behçet Syndrome

    Basak Sirin1, Sinem Nihal Esatoglu2, Hasan Yazıcı3 and Gulen Hatemi4, 1Istanbul University- Cerrahpaşa, Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey, 2Istanbul University- Cerrahpaşa, Cerrahpaşa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul,Türkiye/Istanbul University- Cerrahpaşa, Behcet's Disease Research Center, Istanbul, Turkey, 3Academic Hospital, Istanbul, Turkey, 4Istanbul University- Cerrahpaşa, Cerrahpaşa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul,Türkiye/Istanbul University- Cerrahpaşa, Behcet's Disease Research Center, Istanbul,Türkiye, Istanbul, Turkey

    Background/Purpose: Previous randomized controlled studies reported conflicting results regarding the effectiveness of colchicine on oral ulcers in Behçet syndrome (BS). A randomized drug discontinuation design…
  • Abstract Number: L10 • ACR Convergence 2024

    Neuroimmune Modulation in Adults with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological or Targeted Synthetic DMARDs: Results at 12 and 24 Weeks from a Randomized, Sham-Controlled, Double-Blind Pivotal Study

    John Tesser1, Joshua June2, Pendleton Wickersham3, Jane Box4, Guillermo Valenzuela5, Angela Crowley6, Nikila Kumar7, Norman Gaylis8, Gordan Lam9, David Ridley10, Gineth Paola Pinto-Patarroyo11 and David Chernoff12, 1Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, 2Great Lakes Center of Rheumatology, Lansing, MI, 3Arthritis Associates PA, San Antonio, TX, 4DJL Clinical Research, PLLC, Charlotte, NC, 5Guillermo Valenzuela MD PA/ IRIS Rheumatology, Plantation, FL, 6Illinois Bone and Joint Institute - Hinsdale Orthopaedics, Hinsdale, IL, 7Arizona Arthritis & Rheumatology Associates, Scottsdale, AZ, 8Arthritis & Rheumatic Disease Specialties, Aventura, FL, 9Arthritis & Osteoporosis Consults of the Carolinas, Charlotte, NC, 10St. Paul Rheumatology, Eagan, MN, 11Annapolis Rheumatology, Fairfax, VA, 12SetPoint Medical, Sausalito, CA

    Background/Purpose: In this study, we evaluated the safety and efficacy of an implantable, cervical vagus nerve stimulation device for treatment of RA. Methods: This randomized,…
  • Abstract Number: L04 • ACR Convergence 2024

    Performance of an Artificial Intelligence Model Compared to Multiple Human Experts in Scoring Synovitis Severity and Osteophyte Severity on Joint Ultrasound Images

    Anders Weber1, Mads Ammitzbøll Danielsen2, Bill Aplin Frederiksen3, Hilde Berner Hammer4, Benjamin Schultz Overgaard3, Lene Terslev2, Thiusius Rajeeth Savarimuthu5 and Soren Andreas Just3, 1ROPCA, Odense, Denmark, 2Center for Rheumatology and Spine Disease, Rigshospitalet, Glostrup, Denmark, 3Section of Rheumatology, Department of Medicine, Svendborg Sygehus OUH, Svendborg, Denmark, 4Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Faculty of Medicine, University of Oslo, Oslo, Norway, 5Mærsk Mc-Kinney Møller Institute, University of Southern Denmark, Odense, Denmark

    Background/Purpose: To evaluate the agreement of an artificial intelligence (AI) model designed to assess greyscale and Doppler synovitis severity and osteophyte severity in hand joints…
  • Abstract Number: L02 • ACR Convergence 2024

    Persistent Articular Infection and Host Reactive Responses Contribute to Brucella-Induced Spondyloarthritis in SKG Mice

    Jerome Harms1, Jens Eickhoff1, Thomas Warner1 and Judith Smith2, 1University of Wisconsin-Madison, Madison, WI, 2University of Wisconsin, Madison, WI

    Background/Purpose: Brucellosis, one of the most prevalent zoonotic diseases worldwide, often results in osteoarticular complications including large joint and axial arthritis mimicking spondyloarthritis (SpA). Greater…
  • Abstract Number: L01 • ACR Convergence 2024

    Targeted Exosite Inhibition of STING Activation of TBK1 Selectively Blocks Type I Interferon and NFκB Responses for Treatment of Autoimmune Diseases

    Matthew Martin1, Erik Wilker1, Diana Gikunju1, Usha Narayanan1, Unnati Pandya1, Vijetha Prakash1, Ashley Edwards1, Sameer Kawatkar1, Tenghui Chen1, Ragunath Chandran1, Sai Sunder1, Sumathi Biradar1, Joerg Distler2, Alexandra Joseph1, Stephanos Ioannidis1 and Bhavatarini Vangamudi1, 1Exo Therapeutics, Cambridge, MA, 2Exo Therapeutics, Düsseldorf, Germany

    Background/Purpose: The cGAS-TBK1-STING pathway senses nucleic acids for innate immunity. Aberrant activation of the pathway is linked to autoimmune diseases including Systemic and Cutaneous Lupus…
  • Abstract Number: L06 • ACR Convergence 2024

    Distinct Cytokine and Cytokine Receptor Expression Patterns Characterize Different Subtypes of Inflammatory Myopathies

    Raphael Kirou1, Iago Pinal-Fernandez1 and Andrew Mammen2, 1NIAMS/National Institutes of Health, Bethesda, MD, 2NIH, Bethesda, MD

    Background/Purpose: Myositis is a term for a heterogeneous group of inflammatory myopathies, each with characteristic clinical manifestations, histopathological features, and autoantibodies, including myositis-specific autoantibodies (MSAs).…
  • Abstract Number: L05 • ACR Convergence 2024

    Prolonged Plasma Urate-Lowering After a Single Intravenous Administration of PRX-115, a Novel PEGylated Uricase, in Participants with Elevated Urate Levels

    Christian Schwabe1, Orit Cohen Barak2, Alexandra Cole3, Hadar Reuveni2, Liron Shelev2, Liora Blinder-Haddad2 and Nicola Dalbeth4, 1NZCR, Auckland, New Zealand, 2Protalix Ltd, Karmiel, Israel, 3NZCR, Christchurch, New Zealand, 4University of Auckland, Auckland, New Zealand

    Background/Purpose: PEGylated uricases have already demonstrated therapeutic modality in the treatment of refractory gout patients. PRX-115 is a recombinant homotetrameric uricase enzyme, produced from Candida…
  • Abstract Number: L12 • ACR Convergence 2024

    A-319, a CD3 X CD19 T Cell Engager (TCE), for the Treatment of Severe/Refractory SLE: Early Evidence of Rapid Reset of Disease-Specific Autoimmunity

    Chunli Mei1, Xin Guan1, Bin Wu2, Mengjiao Li1, Xiaojing Liu1, Xi Chen1, You Song1, Weiwei Wang1, Cheng Wang1, Huiling Mei1, Xiaoru Duan1, Lijuan Jiang1, Wenlin Qiu1, Likai Yu1, Yuhong Liu1, Xing Zhao3, Xuanfan Zhong3, Shengjie Xue3, Wuzhong Shen3, Ying Tan3, Guojian Yu3, Guiyun Tu3, Hanyang Chen3, Amy Sun3, Xiaoqiang Yan3, Anbing Huang1, Rong Du1 and Qiubai Li1, 1Department of Rheumatology and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 2Department of Rheumatology and Immunology of the First People’s Hospital of Jingzhou, Jingzhou, China, 3ITabMed Ltd. Changchun, Shanghai, China

    Background/Purpose: CD19 CAR T treatment has demonstrated clinical benefits to patients with severe/refractory systemic lupus erythematosus (SLE), possibly due to resetting autoimmunity. A-319, a highly…
  • Abstract Number: L03 • ACR Convergence 2024

    CD9 Expressing T Follicular Helper Cells Are a Highly Functional Subset Expanded in Systemic Lupus Erythematosus

    Kyleigh Brimmer1, Olivia Antao1, Daniel Mayer1, Gina Sanchez1, Rebecca Francis1, Htay Htay Kyi2, Mary Salim2, Boyan Xia2, Eugenio Capitle2 and Jason Weinstein1, 1Center for Immunity and Inflammation, Rutgers New Jersey Medical School, Newark, NJ, 2Division of Allergy, Immunology and Rheumatology, University Hospital, Newark, NJ

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by the generation of autoantibodies that promote tissue injury. The development of pathogenic autoantibody-secreting B cells in lupus…
  • 1
  • 2
  • 3
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology